Endoscopic gut reset shows promise to preserve weight loss after GLP-1 therapy

A blinded, sham-controlled trial presented at DDW 2026 suggests that duodenal mucosal resurfacing, a minimally invasive endoscopic procedure, may help people retain most of their GLP-1–driven weight loss after stopping Ozempic/semaglutide. In the early REMAIN-1 data (45 participants: 29 treated, 16 sham), those who received resurfacing regained significantly less weight than controls six months after discontinuing the drug, with some patients regaining as little as ~7 pounds and keeping over 80% of their weight loss; no serious complications were reported and recovery is quick. The regimen is investigational, with larger topline results from REMAIN-1 anticipated later in 2026.